Prestige BioPharma, a Singapore-based Kosdaq-listed pharmaceutical company said Tuesday that the company has joined the Cancer Moonshot Project, a White House initiative aimed at advancing cancer prevention and treatment. The Cancer Moonshot initiative was first launched in 2016 and relaunched in 2022 by US President Joe Biden. The goal of the initiative is to cut the cancer death rate by 50 percent in the next 25 ye.